Skip to main content
Caplight Logo









Chimagen Biosciences

Chimagen Biosciences

Private
ShanghaiHealthcare & Life Scienceshttp://www.chimagen.com/index.html

Last Round

M&A

Oct 29, 2024

Company Overview

Chimagen Biosciences is a clinical-stage biotechnology company that discovers and develops multi-specific T cell-engagers and NK cell-engagers for the treatment of cancer and autoimmune diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

multispecific antibodyT-cell engagerbiotechoncologybispecific antibodyimmunotherapydrug discoverybiologicsclinical-stage biotechantibody engineeringcancer therapydrug developmentbiopharmaclinical trialR&D

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Chimagen Biosciences Comparables

Compare Chimagen Biosciences with similar companies based on industry and business-model similarity.

Chimagen Biosciences comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Innovent Biologics
82%
Harbour BioMed
79%
AstraZeneca
78%

Chimagen Biosciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
M&AOct 29, 2024
Series BOct 1, 2024

Key People

Founding team and executive leadership

Zhenhao Zhou

Founder and CEO

Founding Team

Chimagen Biosciences Investors

Notable investors and investment history

Chimagen Biosciences investors
InvestorRounds
Foresite CapitalSeries B
Lilly Asia VenturesSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Oct 29, 2024

    $300M round led by GSK plc.

Chimagen Biosciences Filings

Explore SEC and related filing metadata, where available.

Chimagen Biosciences filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Chimagen Biosciences's valuation, stock price, and market status.

Is Chimagen Biosciences a public or private company?

Chimagen Biosciences is a private company.

What is the current stock price of Chimagen Biosciences?

Chimagen Biosciences is a private company with no public stock price. No recent secondary market data is available.

How much is Chimagen Biosciences worth (valuation)?

Valuation information for Chimagen Biosciences is not publicly available.

Can I buy Chimagen Biosciences stock?

Chimagen Biosciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Chimagen Biosciences's last funding round?

Chimagen Biosciences's most recent funding round was M&A on October 29, 2024.

Who are the main investors in Chimagen Biosciences?

Key investors in Chimagen Biosciences include Foresite Capital, Lilly Asia Ventures.

Will Chimagen Biosciences IPO soon?

No public IPO plans have been announced for Chimagen Biosciences.

How can I track Chimagen Biosciences secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Chimagen Biosciences's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersShanghai
Employee Range4
Year Founded2016
Last FundingOct 29, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?